Abstract:Currently licensed glycoconjugate vaccines are composed of a carbohydrate moiety covalently linked to a protein carrier. Polysaccharides are T-cell independent antigens able to directly stimulate B cells to produce antibodies. Disease burden caused by polysaccharide-encapsulated bacteria is highest in the first year of life, where plain polysaccharides are not generally immunogenic, limiting their use as vaccines. This limitation has been overcome by covalent coupling carbohydrate antigens to proteins that provide T cell epitopes. In addition to the protein carriers currently used in licensed glycoconjugate vaccines, there is a search for new protein carriers driven by several considerations: (i) concerns that pre-exposure or co-exposure to a given carrier can lead to immune interference and reduction of the anti-carbohydrate immune response; (ii) increasing interest to explore the dual role of proteins as carrier and protective antigen; and (iii) new ways to present carbohydrates antigens to the immune system. Protein carriers can be directly coupled to activated glycans or derivatized to introduce functional groups for subsequent conjugation. Proteins can be genetically modified to pre-determine the site of glycans attachment by insertion of unnatural amino acids bearing specific functional groups, or glycosylation consensus sequences for in vivo expression of the glycoconjugate. A large portion of the new protein carriers under investigation are recombinant ones, but more complex systems such as Outer Membrane Vesicles and other nanoparticles are being investigated. Selection criteria for new protein carriers are based on several aspects including safety, manufacturability, stability, reactivity toward conjugation, and preclinical evidence of immunogenicity of corresponding glycoconjugates. Characterization panels of protein carriers include tests before conjugation, after derivatization when applicable, and after conjugation. Glycoconjugate vaccines based on non-covalent association of carrier systems to carbohydrates are being investigated with promising results in animal models. The ability of these systems to convert T-independent carbohydrate antigens into T-dependent ones, in comparison to traditional glycoconjugates, needs to be assessed in humans.

Design And Development Of Glycoconjugate Vaccines

Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends

Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments

Modeling 1-Cyano-4-dimethylaminopyridine Tetrafluoroborate (CDAP) Chemistry to Design Glycoconjugate Vaccines with Desired Structural and Immunological Characteristics

Development of an Efficacious, Semisynthetic Glycoconjugate Vaccine Candidate against Streptococcus pneumoniae Serotype 1

Chemical Synthesis of Glycans and Applications in Carbohydrate-Based Vaccines

Carriers and Antigens: New Developments in Glycoconjugate Vaccines

Polysaccharide conjugate vaccine: A kind of vaccine with great development potential

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models

A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines

A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms

Sugar-Coated: Can Multivalent Glycoconjugates Improve upon Nature's Design?

Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines

Harnessing galactose oxidase in the development of a chemoenzymatic platform for glycoconjugate vaccine design

Classical- and bioconjugate vaccines: comparison of the structural properties and immunological response

A Multidisciplinary Structural Approach to the Identification of the Haemophilus influenzae Type b Capsular Polysaccharide Protective Epitope

Synthesis of glycoimmunogen Tn-Thr-PS A1 via hydrazone bond and stability optimization of PS A1 monosaccharide mimics under vaccine development conditions

Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine

Covalent Bond or Noncovalent Bond: A Supramolecular Strategy for the Construction of Chemically Synthesized Vaccines

Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach